References
Kitchens CS (2011) How I treat superficial venous thrombosis. Blood 117:39–44
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e419S–e496S
Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, Laporte S, Matyas L, Middeldorp S, Sokurenko G, Leizorovicz A; CALISTO Study Group (2010) Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 363:1222–1232
Beyer-Westendorf J (2017) Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis. Haematology Am Soc Hematol Educ Program 2017:223–230
Bates SM, Rajasekhar A, Middeldorp S, McLintock C, Rodger MA, James AH, Vazquez SR, Greer IA, Riva JJ, Bhatt M, Schwab N, Barreett D, LaHaye A, Rochwerg B (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2:3317–3359
Ho P, Lim HY, Chua CC, Sleeman M, Tacey M, Donnan G, Nandurkar H (2016) Retrospective review on isolated distal deep vein thrombosis (IDDVT)—a benign entity or not? Thromb Res 142:11–16
Lim HY, Chua CC, Tacey M, Sleeman M, Donnan G, Nandurkar H, Ho P (2017) Venous thromboembolism management in Northeast Melbourne: how does it compare to international guidelines and data? Internal Med J 47:1034–1042
Decousus H, Quéré I, Presles E, Becker F, Barrellier M-T, Chanut M, Gillet J-L, Guenneguez H, Leandri C, Mismetti P (2010) Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 152:218–224
Cosmi B, Fillippini M, Campana F, Avruscio G, Ghirarduzzi A, Bucherini E, Camporese G, Imberti D, Legnani C, Palareti G; STEFLUX Investigators (2014) Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thromb Res 133:196–202
Lozano FS, Almazan A (2003) Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. Vasc Endovasc Surg 37:415–420
Beyer-Westendorf J, Schellong SM, Gerlach H, Rabe E, Weitz JI, Jersemann K, Sahin K, Bauersachs R; SURPRISE Investigators (2017) Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 4:e105–e113
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lui, B., Ho, P. & Lim, H.Y. Superficial venous thrombosis: is it as benign as we think?. J Thromb Thrombolysis 50, 416–420 (2020). https://doi.org/10.1007/s11239-020-02059-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-020-02059-x